Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8871120 | 0.82 | TSHR (0.34) | NOTUMPOLBALDH1A1KDM4EGLA | |
| SCHEMBL9581901 | 0.81 | BCHE (0.35) | NOTUMPOLBKDM4EHPGDHSD17B10 | |
| SCHEMBL9581907 | 0.80 | KMT2A (0.46) | ALDH1A1KDM4EHSD17B10LMNAEGFR | |
| SCHEMBL15474750 | 0.78 | RAB9A (0.50) | ALDH1A1KDM4EHPGDGAALMNA | |
| SCHEMBL9582187 | 0.78 | ALDH1A1 (0.43) | POLBALDH1A1KDM4EHSD17B10GAA | |
| SCHEMBL13834141 | 0.77 | NOTUM (0.33) | NOTUM | |
| SCHEMBL4853728 | 0.77 | CYP2D6 (0.33) | HTTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL1948855 | 0.76 | BCHE (0.44) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL5462632 | 0.70 | F12 (0.52) | POLBALDH1A1KDM4EHSD17B10MEN1 | |
| SCHEMBL154929 | 0.69 | EGFR (0.36) | POLBALDH1A1KDM4ELMNACREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113072467-B | Substituted guanidino-containing derivative and application thereof in preparing osteoclast differentiation inhibitor | 南方医科大学 | 2022-04-12 | — | — | CN | claimed |
| CN-113072467-A | Substituted guanidino-containing derivative and application thereof in preparing osteoclast differentiation inhibitor | 南方医科大学 | 2021-07-06 | — | — | CN | claimed |
| EP-3323816-B1 | NOVEL PYRAZOLE DERIVATIVE | GREEN TECHNOLOGY CO LTD (JP) | 2019-07-03 | — | — | EP | claimed |
| EP-3323816-A1 | NOVEL PYRAZOLE DERIVATIVE | Green Tech Co., Ltd. (JP) | 2018-05-23 | — | — | EP | claimed |
| US-9399635-B2 | Pyrazole derivative | GREEN TECH CO., LTD. (JP) | 2016-07-26 | — | — | US | claimed |
| US-8962674-B2 | Curcumin derivative | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-02-24 | — | — | US | claimed |
| US-20140142094-A1 | KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-05-22 | — | — | US | claimed |
| US-20140088029-A1 | NOVEL PYRAZOLE DERIVATIVE | PHARMA EIGHT CO., LTD. (JP) | 2014-03-27 | — | — | US | claimed |
| EP-2702064-A1 | KINASE INHIBITORS | Icahn School of Medicine at Mount Sinai (US) | 2014-03-05 | — | — | EP | claimed |
| CN-103619854-A | Kinase inhibitors | SINAI SCHOOL MEDICINE | 2014-03-05 | — | — | CN | claimed |
| EP-0966456-A4 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | RES FOUNDATION OF (US) | 2000-07-26 | — | — | EP | claimed |
| EP-0966456-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0903349-A2 | CCR-3 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-24 | — | — | EP | claimed |
| US-5811452-A | ADMINISTERING WITH PACLITAXEL OR DOXORUBICIN | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-09-22 | — | — | US | claimed |
| EP-0833629-A4 | ARYL ACRYLIC ACID DERIVATIVES USEFUL AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ONTOGEN CORP (US) | 1998-09-16 | — | — | EP | claimed |
| WO-1998030553-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-07-16 | — | — | WO | claimed |
| US-5770620-A | ENZYME INHIBITOR AS IMMUNOMODULATORS | ONTOGEN CORPORATION (US) | 1998-06-23 | — | — | US | claimed |
| EP-0833629-A2 | ARYL ACRYLIC ACID DERIVATIVES USEFUL AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ONTOGEN CORPORATION (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1997008934-A2 | ARYL ACRYLIC ACID DERIVATIVES USEFUL AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ONTOGEN CORPORATION (US) | 1997-03-13 | — | — | WO | claimed |
| US-4355823-A | Pressure-sensitive or heat-sensitive recording material | CIBA-GEIGY CORPORATION (US) | 1982-10-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142094-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | NOTUM 3329/4885POLB 669/4885HTT 3293/4885 |
| US-20140088029-A1 | NOVEL PYRAZOLE DERIVATIVE | PSEN2, MAPT, PSEN1 | NOTUM 4256/4885POLB 4181/4885HTT 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.